Coronary artery thrombosis and elevated urine immunoreactive thromboxane B2

Area of Science:

• Cardiology
• Biochemistry
• Diagnostic Medicine

Background:

• Thromboxane B2 (TXB2) is a marker of platelet activation.
• Early detection of myocardial infarction (MI) is crucial for patient outcomes.
• Differentiating MI from angina pectoris can be challenging.

Purpose of the Study:

• To investigate the role of immunoreactive thromboxane B2 (i-TXB2) in the diagnosis of myocardial infarction.
• To assess whether urinary i-TXB2 levels can distinguish MI from angina pectoris.
• To explore the temporal relationship between i-TXB2 levels and infarction events.

Main Methods:

• Radio-immunoassay (RIA) was used to measure urinary i-TXB2.
• Urine samples were collected from patients admitted with suspected MI, including confirmed MI, pulmonary embolism, and angina pectoris.
• Serial urine collections were performed in some MI patients.

Main Results:

• Patients with confirmed MI showed significantly higher urinary i-TXB2 levels on admission compared to patients with angina (2.72 vs. 0.51 ng/ml).
• Urinary i-TXB2 levels decreased by 24 hours in MI patients (1.58 ng/ml).
• In one case, i-TXB2 levels peaked three days prior to MI diagnosis, suggesting pre-infarction platelet activation.

Conclusions:

• Elevated urinary i-TXB2 is associated with myocardial infarction.
• Urinary i-TXB2 may serve as a valuable biomarker for differentiating myocardial infarction from angina.
• Findings suggest thromboxane release from activated platelets precedes infarction events.